Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: A retrospective analysis of patient-level data in placebo-controlled studies

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 5, 2015, Pages 607-613

  Estborn, L ^a   Joelson, S ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CAUSAL ATTRIBUTION; CHILD; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DRUG USE; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; GENERAL PATHOLOGICAL PARAMETERS; HUMAN; INFANT; INFECTION RATE; INFECTION RISK; LARYNGOPHARYNGEAL REFLUX; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NONCARDIAC CHEST PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLUX ASTHMA; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; TIME TO ONSET OF INFECTION; AGE; COMMUNITY-ACQUIRED INFECTIONS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PNEUMONIA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTIONS; SEX DIFFERENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESOMEPRAZOLE; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PNEUMONIA; PROTON PUMP INHIBITORS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 84938548378     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13304     Document Type: Article

References (26)

1. El-Serag HB, Sweet S, Winchester CC, Dent J,. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871-80.
2. Sung JJY, Kuipers EJ, El-Serag HB,. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29: 938-46.
3. McKeage K, Blick SK, Croxtall JD, Lyseng-Williamson KA, Keating GM,. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008; 68: 1571-607.
4. Reimer C,. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27: 443-54.
5. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB,. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-60.
6. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB,. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003; 18: 847-51.
7. Rousseau MC, Catala A, Blaya J,. Association between pulmonary and digestive infections in patients receiving gastric acid-lowering medications for a long duration. Brain Inj 2003; 17: 883-7.
8. Canani RB, Cirillo P, Roggero P, et al,. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117: e817-20.
9. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J,. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-5.
10. Giuliano C, Wilhelm SM, Kale-Pradhan PB,. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5: 337-44.
11. Rodriguez LA, Ruigomez A, Wallander MA, Johansson S,. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology 2009; 20: 800-6.
12. Spechler SJ,. Risk of community-acquired pneumonia after acid-suppressive drugs. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 72-3.
13. Johnstone J, Nerenberg K, Loeb M,. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165-77.
14. Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV,. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012; 54: 33-42.
15. US Food and Drug Administration. Potential signals of serious risks/new safety information identified by the adverse event reporting system (AERS) between April-June 2012. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm324020.htm (accessed 3 April 2014).
16. Filion KB, Chateau D, Targownik LE, et al,. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63: 552-8.
17. Sultan N, Nazareno J, Gregor J,. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008; 22: 761-6.
18. 2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19: 792-802.
19. Estborn L, Joelson S,. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008; 31: 627-36.
20. Gregor JC,. Acid suppression and pneumonia: a clinical indication for rational prescribing. JAMA 2004; 292: 2012-3.
21. Detsky ME, Juurlink DN,. Does gastric acid suppression increase the risk of community-acquired pneumonia? CMAJ 2005; 172: 331.
22. Sataloff RT,. Community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2005; 293: 795-6.
23. Jena AB, Sun E, Goldman DP,. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013; 28: 223-30.
24. Gaude GS,. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med 2009; 4: 115-23.
25. El-Serag HB, Sonnenberg A,. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997; 113: 755-60.
26. Sarkar M, Hennessy S, Yang YX,. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-8.